153 related articles for article (PubMed ID: 20303217)
1. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research.
Grutters JP; Pijls-Johannesma M; Ruysscher DD; Peeters A; Reimoser S; Severens JL; Lambin P; Joore MA
Cancer Treat Rev; 2010 Oct; 36(6):468-76. PubMed ID: 20303217
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
Sher DJ; Wee JO; Punglia RS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.
Louie AV; Rodrigues G; Hannouf M; Zaric GS; Palma DA; Cao JQ; Yaremko BP; Malthaner R; Mocanu JD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):964-73. PubMed ID: 20932688
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
[TBL] [Abstract][Full Text] [Related]
5. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
Lanni TB; Grills IS; Kestin LL; Robertson JM
Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
[TBL] [Abstract][Full Text] [Related]
7. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
Carlson JJ; Reyes C; Oestreicher N; Lubeck D; Ramsey SD; Veenstra DL
Lung Cancer; 2008 Sep; 61(3):405-15. PubMed ID: 18295368
[TBL] [Abstract][Full Text] [Related]
8. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons.
Peeters A; Grutters JP; Pijls-Johannesma M; Reimoser S; De Ruysscher D; Severens JL; Joore MA; Lambin P
Radiother Oncol; 2010 Apr; 95(1):45-53. PubMed ID: 20106540
[TBL] [Abstract][Full Text] [Related]
9. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer.
Iwata H; Murakami M; Demizu Y; Miyawaki D; Terashima K; Niwa Y; Mima M; Akagi T; Hishikawa Y; Shibamoto Y
Cancer; 2010 May; 116(10):2476-85. PubMed ID: 20225229
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of radiotherapy, carbon ion therapy, proton therapy and BNCT in Japan.
Nakagawa Y; Yoshihara H; Kageji T; Matsuoka R; Nakagawa Y
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S80-3. PubMed ID: 19394238
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
van den Hout WB; Kramer GW; Noordijk EM; Leer JW
J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
Paix A; Noel G; Falcoz PE; Levy P
Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.
Hadziahmetovic M; Loo BW; Timmerman RD; Mayr NA; Wang JZ; Huang Z; Grecula JC; Lo SS
Discov Med; 2010 May; 9(48):411-7. PubMed ID: 20515609
[TBL] [Abstract][Full Text] [Related]
16. Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: a dosimetric comparison with photon-based stereotactic body radiotherapy.
Hoppe BS; Huh S; Flampouri S; Nichols RC; Oliver KR; Morris CG; Mendenhall NP; Li Z
Radiother Oncol; 2010 Dec; 97(3):425-30. PubMed ID: 20934768
[TBL] [Abstract][Full Text] [Related]
17. Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis.
Louie AV; Rodrigues G; Hannouf M; Lagerwaard F; Palma D; Zaric GS; Haasbeek C; Senan S
Radiother Oncol; 2011 May; 99(2):161-5. PubMed ID: 21620503
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of proton radiation therapy in the treatment of breast cancer.
Lundkvist J; Ekman M; Ericsson SR; Isacsson U; Jönsson B; Glimelius B
Radiother Oncol; 2005 May; 75(2):179-85. PubMed ID: 15885828
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
Wolff HB; Alberts L; van der Linden N; Bongers ML; Verstegen NE; Lagerwaard FJ; Hofman FN; Uyl-de Groot CA; Senan S; El Sharouni SY; Kastelijn EA; Schramel FMNH; Coupé VMH
Lung Cancer; 2020 Mar; 141():89-96. PubMed ID: 31982640
[TBL] [Abstract][Full Text] [Related]
20. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis.
Macdonald OK; Kruse JJ; Miller JM; Garces YI; Brown PD; Miller RC; Foote RL
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):950-8. PubMed ID: 19801106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
